64 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
19 Mar 24
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
4:17pm
Innovative Licensing and Access Pathway (ILAP) designation for TSHA-102 from U.K. MHRA. The ILAP aims to facilitate patient access to novel … and has been granted Orphan Drug designation from the European Commission. TSHA-102 has also received Innovative Licensing and Access Pathway designation
8-K
EX-10.1
TSHA
Taysha Gene Therapies Inc
20 Dec 23
Departure of Directors or Certain Officers
4:21pm
controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic
S-8
EX-99.1
TSHA
Taysha Gene Therapies Inc
20 Dec 23
Registration of securities for employees
4:20pm
controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic
8-K
EX-10.1
7pxx38
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
DEFA14A
euex1i6bo5i40e8ba6x5
8 May 23
Additional proxy soliciting materials
4:04pm
PRE 14A
zebr73 djc22sb6d8o
27 Apr 23
Preliminary proxy
4:03pm
8-K
EX-99.1
sggq5h
8 Nov 22
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:06am
8-K/A
EX-10.3
y5jj19uqn 5sbsg2cj
31 Oct 22
Entry into a Material Definitive Agreement
8:45am
8-K/A
EX-10.2
b4dw205ez7i6b52dcz
31 Oct 22
Entry into a Material Definitive Agreement
8:45am
8-K/A
EX-10.1
lo60a 6alb
31 Oct 22
Entry into a Material Definitive Agreement
8:45am